(19)
(11) EP 3 130 582 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.01.2019 Bulletin 2019/01

(45) Mention of the grant of the patent:
10.10.2018 Bulletin 2018/41

(21) Application number: 15786179.0

(22) Date of filing: 29.04.2015
(51) International Patent Classification (IPC): 
C07C 279/26(2006.01)
A61P 37/00(2006.01)
A61K 31/155(2006.01)
(86) International application number:
PCT/KR2015/004299
(87) International publication number:
WO 2015/167243 (05.11.2015 Gazette 2015/44)

(54)

COMPOUND HAVING IMMUNE DISEASE TREATMENT EFFECT AND USE THEREOF

VERBINDUNG MIT IMMUNERKRANKUNGBEHANDLUNGSWIRKUNG UND VERWENDUNG DAVON

COMPOSÉ AYANT UN EFFET THÉRAPEUTIQUE SUR LES MALADIES IMMUNITAIRES ET UTILISATION DE CE COMPOSÉ


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 29.04.2014 KR 20140051261

(43) Date of publication of application:
15.02.2017 Bulletin 2017/07

(73) Proprietor: The Catholic University of Korea Industry-Academic Cooperation Foundation
Seoul 137-701 (KR)

(72) Inventors:
  • CHO, Mi-La
    Seoul 140-854 (KR)
  • SHIN, Dong-Yun
    Seoul 135-906 (KR)
  • PARK, Sung-Hwan
    Seoul 137-779 (KR)
  • YANG, Chul- Woo
    Seoul 137-764 (KR)
  • CHOI, Jong-Young
    Seoul 137-855 (KR)
  • PARK, Min-Jung
    Seoul 152-781 (KR)
  • SON, Hye-Jin
    Seoul 150-833 (KR)
  • LEE, Sung-Hee
    Seoul 156-803 (KR)
  • LEE, Seon-Yeong
    Seoul 157-883 (KR)
  • KIM, Eun-Kyung
    Seoul 139-937 (KR)
  • KIM, Jae-kyung
    Seoul 151-849 (KR)
  • LEE, Seung-Hun
    Goyang-si Gyeonggi-do 10412 (KR)
  • PARK, Seong-Hyeok
    Yeongju-si Gyeongsangbuk-do 36132 (KR)

(74) Representative: Turner, Craig Robert et al
A.A. Thornton & Co. 10 Old Bailey
London EC4M 7NG
London EC4M 7NG (GB)


(56) References cited: : 
WO-A2-03/084475
KR-A- 20110 053 837
KR-A- 20140 036 598
US-A- 4 183 956
US-A1- 2013 095 140
WO-A2-03/089601
KR-A- 20110 081 095
US-A- 4 060 635
US-A1- 2011 053 941
   
  • H. C. CARRINGTON ET AL: "Synthetic antimalarials. Part XLIX. The structure and synthesis of the dihydrotriazine metabolite of proguanil", JOURNAL OF THE CHEMICAL SOCIETY (RESUMED), 1 January 1954 (1954-01-01), pages 1017-1031, XP055061878, ISSN: 0368-1769, DOI: 10.1039/jr9540001017
  • SHAPIRO S L ET AL: "HYPOGLYCEMIC AGENTS. II. ARYLBIGUANIDES", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 81, 20 July 1959 (1959-07-20), pages 3725-3728, XP001160743, AMERICAN CHEMICAL SOCIETY, US ISSN: 0002-7863, DOI: 10.1021/JA01523A059
  • DATABASE PubChem Compound [Online] 20 October 2014 (2014-10-20), XP055390088, Database accession no. AKOS021352901
  • DATABASE PubChem Compound [Online] 20 October 2014 (2014-10-20), XP055390098, Database accession no. AKOS021352899
  • DATABASE PubChem Compound [Online] 30 November 2012 (2012-11-30), XP055390103, Database accession no. CID 68132850
  • RICHARD A. GLENNON ET AL: "Arylguanidine and arylbiguanide binding at 5-HT3 serotonin receptors: A QSAR study", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 11, no. 20, 1 October 2003 (2003-10-01), pages 4449-4454, XP055390154, GB ISSN: 0968-0896, DOI: 10.1016/S0968-0896(03)00488-7
  • CURD F H S ET AL: "SYNTHETIC ANTIMALARIALS. PART IV. 2-PHENYLGUANIDINO-4-AMINOALKYLAMINO-6-METH YLPYRIMIDINES", JOURNAL OF THE CHEMICAL SOC, 1 January 1946 (1946-01-01), pages 362-366, XP009022670, CHEMICAL SOCIETY, LETCHWORTH; GB ISSN: 0368-1769, DOI: 10.1039/JR9460000362
  • DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 25 February 2014 (2014-02-25), XP002772055, Database accession no. 1555308-85-4
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).